TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
TLX - TELIX PHARMACEUTICALS LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX200 | ASX300 | ALL-ORDS
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$7.07
20 Mar |
OPEN $7.23 |
HIGH $7.34 |
1,046,635 LOW $7.03 |
-0.160| OTHER COMPANIES IN THE SAME SECTOR | |||
| CUV . ACR . AHZ . CSL . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . OCC . ACW . AVH . LGP . SPL . ARX . AFP . 1AD . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . HXL . MXC . MAP . CAU . OPT . ANP . TRP . BIO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | -33.5 |
| DPS All | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | 160.1 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | 25.3 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | -64.0 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | -65.01 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | -253.34 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | -221.73 % |
| Return on Assets | xxx | xxx | xxx | xxx | -56.20 % |
| Return on Equity | xxx | xxx | xxx | xxx | -253.34 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | -153.82 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | -71.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
This is work in progress. Bear with us. It'll be amazing.
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
TLX STOCK CHART
FNArena News on TLX
| 1 |
Australian Broker Call *Extra* Edition – Mar 15, 2023Mar 15 2023 - Daily Market Reports |
| 2 |
Rudi’s View: Fear & Greed (Rinse & Repeat)Mar 15 2023 - Rudi's View |
| 3 |
Australian Broker Call *Extra* Edition – Mar 10, 2023Mar 10 2023 - Daily Market Reports |
| 4 |
Australian Broker Call *Extra* Edition – Mar 06, 2023Mar 06 2023 - Daily Market Reports |
| 5 |
Australian Broker Call *Extra* Edition – Mar 02, 2023Mar 02 2023 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
FDA Approval Puts Rocket Under Neuren SharesMar 16 2023 - Small Caps |
| 2 |
Dr Boreham’s Crucible: Actinogen MedicalNov 30 2022 - Small Caps |
| 3 |
Dr Boreham’s Crucible: Qbiotics GroupNov 09 2022 - Small Caps |
| 4 |
Dr Boreham’s Crucible: PharmaxisOct 05 2022 - Small Caps |
| 5 |
Brokers Review Prospects For CSLSep 30 2022 - Australia |
| 6 |
Dr Boreham’s Crucible: Inoviq LtdSep 19 2022 - Small Caps |
| 7 |
CSL: Offering Buying OpportunitySep 13 2022 - Technicals |
| 8 |
Dr Boreham’s Crucible: Vaxxas Pty LtdSep 07 2022 - FYI |
| 9 |
Dr Boreham’s Crucible: Telix PharmaceuticalsAug 22 2022 - Small Caps |
| 10 |
Dr Boreham’s Crucible: OrthocellJul 26 2022 - Small Caps |
